A Phase 3 interventional study of dexmedetomidine hydrochloride nasal spray and dexmedetomidine hydrochloride nasal spray blank preparation in Preoperative Sedation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is being conducted to evaluate the efficacy and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adrenoceptor agonists or antagonists were used before randomization:Phase 1: Subjects who have received α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization.
Phase 2: Subjects who have received selective α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group, subjects received a higher dose of dexmedetomidine hydrochloride nasal spray.
Drug: dexmedetomidine hydrochloride nasal spray
In this group, subjects received a lower dose of dexmedetomidine hydrochloride nasal spray
Drug: dexmedetomidine hydrochloride nasal spray
In the placebo group, subjects received dexmedetomidine hydrochloride nasal spray blank preparation.
Drug: dexmedetomidine hydrochloride nasal spray blank preparation
dexmedetomidine hydrochloride nasal spray
dexmedetomidine hydrochloride nasal spray blank preparation
Proportion of subjects who attained a Ramsay Sedation Score ≥3 at least once within 45 minutes
Evaluated with Ramsay sedation scale Score Response 1. Anxious or restless or both 2. Cooperative, orientated and tranquil 3. Responding to commands 4. Brisk response to stimulus 5. Sluggish response to stimulus 6. No response to stimulus
Time frame: 0 minutes to 45 minutes after administration
Stage I : Propofol infusion rate (mg/kg/h) from the initiation of anesthetic induction until the first time BIS value ≤60 is achieved
Time frame: The BIS value reaches 60 for the first time during intraoperative
Stage I : Propofol infusion rate (mg/kg/h) during general anesthesia
Time frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
Stage I : Opioid analgesic infusion rate (μg/kg/min) from the initiation of anesthetic induction until the first time BIS value ≤60 is achieved
Time frame: The BIS value reaches 60 for the first time during intraoperative
Stage I : Opioid analgesic infusion rate (μg/kg/min) during general anesthesia
Time frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
Stage I : The BIS value at the time when Ramsay Sedation Score first reaches ≥3 after study drug administration
Time frame: The Ramsay Sedation Score ≥3 for the first time during intraoperative
Stage I : Anesthesiologist satisfaction rating
The anesthesiologist satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.
Time frame: At the end of surgery when the patient recovers from anesthesia
Stage I : Subjects' satisfaction rating
The subjects' satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.
Time frame: From the end of surgical operation up to 24 hours
Stage II: Total dose of propofol (mg/kg) administered from anesthesia induction to achieve a BIS value ≤60
Time frame: The BIS value reaches 60 for the first time during intraoperative
Stage II: Changes in BIS value from baseline at 15, 30, and 45 minutes after study drug administration.
Time frame: 15, 30, and 45 minutes after study drug administration
Stage II: Anesthesiologist satisfaction rating
The anesthesiologist satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0
Time frame: At the end of surgery when the patient recovers from anesthesia
Stage II: Time from the start of study drug administration to the first achievement of Ramsay Sedation Score ≥3
Time frame: From administration to the beginning of anesthesia
Safety Endpoints ( Stage I / Stage II) : Incidence and severity of adverse events
Time frame: Within 2 days after study drug administration
Ran from May 2020 to primary completion in Jun 2021, 12 months.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2021 → Jun 2021, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Jiangsu HengRui Medicine Co., Ltd. →